The Board of Pharmacy has received notice of the following product withdrawal:

Eli Lilly and Company is initiating a market withdrawal of all in-date lots of Lartruvo® (olaratumab) 500mg/50 ml x 1 vial and 190mg / 19 ml x 1 vial following discussions with the U.S. Food and Drug Administration (FDA).

Product Description	**NDC Number**
Lartruvo® (olaratumab) 500mg/50 ml x 1 vial	0002-8926-0 I
Lartruvo® (olaratumab) 190mg/ 19 ml x 1 vial	0002-7190 -01

On 25 April 2019, Lilly issued a press release announcing that the company has been working to facilitate the withdrawal of Lartruvo® (olaratumab) from global markets for the treatment of advanced soft tissue sarcoma (STS). Lilly's actions to withdraw Lartruvo® from the market follow the failure of the Phase 3 ANNOUNCE clinical trial, in which Lartruvo® did not improve survival for patients. The withdrawal decision is not related to any safety concern, as the data did not show any new safety signals.

The Board of Pharmacy strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.